<DOC>
	<DOCNO>NCT01325441</DOCNO>
	<brief_summary>This open label , single arm phase 1 dose escalation study phase 2 study BBI608 combination paclitaxel patient advanced malignancy .</brief_summary>
	<brief_title>A Study BBI608 Administered With Paclitaxel Adult Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Signed write informed consent must obtain document accord International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPPA ) prior studyspecific screening procedure 2 . A histologically cytologically confirm ovarian , breast , nonsmall cell lung , melanoma , gastric/GEJ/esophageal type advance cancer metastatic , unresectable , recurrent weekly paclitaxel acceptable therapeutic option . 3 . Patients epithelial ovarian , fallopian tube , primary peritoneal cancer must also meet follow criterion : . Must either platinumresistant platinumrefractory accord follow definition : ( 1 ) Platinumresistant : response platinum therapy follow progression within 6 month complete therapy ( 2 ) Platinumrefractory : best response stable disease progression platinum therapy ; b . Must prior systemic treatment taxane ; c. Must receive 4 prior systemic cytotoxic regimens 4 . Patients melanoma must also meet follow criterion : . If melanoma BRAF wildtype BRAF mutation amenable BRAF inhibitor therapy , patient candidate immunotherapy , must receive ipilimumab ; b . If melanoma positive V600E V600K BRAF mutation , must receive least one line prior therapy BRAFspecific inhibitor ; either alone combination . 5 . Patients triple negative breast cancer ( estrogen receptornegative ( ER ) , progesterone receptornegative ( PR ) , human epidermal growth factor receptor 2negative ( Her2 ) must also meet follow criterion : . Must receive least one prior chemotherapy regimen locally advance metastatic disease ; b . Must receive prior taxane therapy . 6 . Patients NSCLC ( adenocarcinoma , squamous , adenosquamous histopathology ) must also meet follow criterion : . Must disease stage IIIB , curable surgery radiotherapy , stage IV ; b . Must receive least one prior chemotherapy regimen locally advance metastatic disease ; c. EGFRpositive ALKpositive patient must receive least one line EGFRdirected ALKdirected therapy , respectively ; d. Must receive prior taxane therapy . 7 . Patients adenocarcinoma arise esophagus , gastroesophageal junction , stomach must also meet follow criterion : . Must receive prior treatment platinum/fluoropyrimidinebased therapy without anthracycline metastatic setting ; , adjuvant set recurrence occur within 6 month complete systemic adjuvant treatment ; b . Patients HER2 positive tumor must prior treatment Her2 inhibitor ( e.g . trastuzumab lapatinib ) ; c. Patients receive prior taxane therapy may enrol . 8 . ≥ 18 year age 9 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 , see Section 9 ) 10 . Karnofsky performance Status ≥ 70 % ( Section 15 ) 11 . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI608 dose 12 . Females childbearing potential must negative serum pregnancy test 13 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) £1.5 × upper limit normal ( ULN ) , ≤ 2.5 × ULN metastatic liver disease 14 . Hemoglobin ( Hgb ) ≥ 10 g/dl 15 . Total bilirubin £ 1.5 × ULN 16 . Creatinine £ 1.5 ´ ULN creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal 17 . Absolute neutrophil count ³ 1.5 x 109/L 18 . Platelets ≥ 100 x 109/L 19 . Life expectancy ≥ 3 month 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose provide treatmentrelated adverse event resolve deem irreversible , exception single dose radiation 8 Gray ( equal 800 RAD ) palliative intent pain control 7 day begin administration BBI608 . 2 . Surgery within 4 week prior first dose 3 . Any known symptomatic brain metastasis require steroid . Patients treat brain metastasis must stable 4 week completion treatment , image documentation require . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat 4 . Pregnant breastfeed 5 . Significant gastrointestinal disorder ( ) , opinion Principal Investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small intestine resection ) 6 . Unable unwilling swallow BBI608 capsule daily 7 . Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement 8 . Known severe hypersensitivity paclitaxel 9 . Abnormal ECGs ( ie , QT prolongation QTc &gt; 480 msec , sign cardiac enlargement hypertrophy , bundle branch block , sign ischemia necrosis Wolff Parkinson White pattern )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BBI608</keyword>
</DOC>